New shot could stop chronic hives when antihistamines fail
NCT ID NCT06228560
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested a new injectable drug called LP-003 in 202 adults with chronic spontaneous urticaria (long-lasting hives and itching) that standard antihistamines couldn't control. The study compared LP-003 to a placebo and to an existing drug (omalizumab) to see if it could completely stop wheals and itching by week 12. The goal is to find a better option for people whose hives don't respond to usual treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LP-003 (an injectable biologic drug)
What this could lead to
If successful, LP-003 could offer a new treatment option for people with chronic hives that don't respond to standard antihistamines.
What could go wrong
This is an early Phase 2 study with only 202 participants, so results may not hold up in larger trials. The drug may cause side effects or not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Jiangsu University
Zhenjiang, China
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
-
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
-
Hangzhou First People's Hospital
Hangzhou, China
-
Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
Nanjing, Jiangsu, China
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, China
-
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
-
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, China
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
-
The First Affiliated Hospital of China Medical University
Beijing, Beijing Municipality, China
-
The First Affiliated Hospital of PLA Army Medical University
Chongqing, Chongqing Municipality, China
-
The First Hospital of Peking University
Beijing, Beijing Municipality, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
-
The Second XiangYa Hospital of Central South University
Changsha, Hunan, China
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
-
Wuhan NO.1 Hospital
Wuhan, China
-
the Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China